We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 186

Pharma in brief - Federal Court recommendations on “increased proportionality in complex litigation” impact Canadian pharmaceutical patent litigation
  • Norton Rose Fulbright Canada LLP
  • Canada
  • July 3 2015

The Federal Court issued a Notice to the Parties and the Profession dated June 24, 2015 (the "Notice") containing its initial recommendations


Pharma in brief - official publication of amended PM(NOC) Regulations now available patents claiming single medicinal ingredients are eligible for listing on the Patent Register for combination drugs
  • Norton Rose Fulbright Canada LLP
  • Canada
  • June 30 2015

The amendments to the Patented Medicines (Notice of Compliance)Regulations (PM(NOC) Regulations), as brought into force on June 19, 2015 (the


Pharma in brief - amended PM(NOC) Regulations now in force patents claiming single medicinal ingredients are eligible for listing on the patent register for combination drugs
  • Norton Rose Fulbright LLP
  • Canada
  • June 26 2015

Previously announced amendments to the Patented Medicines (Notice of Compliance) Regulations (PM(NOC) Regulations) were registered and brought


Le secret professionnel entre agents de brevets et clients devient loi !
  • Norton Rose Fulbright Canada LLP
  • Canada
  • June 25 2015

Vous vous rappelez le billet de mon collègue Pierre intitulé Fameuses nouvelles dans le Budget fédéral ! ? Eh bien, le projet de loi en question


Finalement, une partie du “file wrapper” en ligne à l’OPIC!
  • Norton Rose Fulbright Canada LLP
  • Canada
  • June 19 2015

Faut le voir pour le croire On l’avait annoncée, l’informatisation des dossiers de brevets à l’OPIC (Office de la propriété intellectuelle du Canada


Federal Court of Appeal affirms rejection of heightened sound prediction patent disclosure requirements
  • Norton Rose Fulbright Canada LLP
  • Canada
  • June 12 2015

Allergan obtained a prohibition order against Apotex under section 6 of the PMNOC Regulations with respect to the drug bimatoprost


Contrefaçon de clavier de blackberry : C’est réglé!
  • Norton Rose Fulbright Canada LLP
  • Canada
  • June 2 2015

Pour conclure la série de billets sur l’affaire des claviers brevetés par Blackberry, et les accusations de contrefaçon ICI, un règlement


Pharma in brief - blinded expert evidence favoured: Court dismisses PM(NOC) application for ciclesonide
  • Norton Rose Fulbright Canada LLP
  • Canada
  • May 19 2015

Takeda Canada Inc. and Takeda GMBH (Takeda) brought an application under section 6 of the PM(NOC) Regulations for an order prohibiting


Pharma in brief - SCC invited to revisit key patent issues: standard of review of claims construction and the patentability of methods of medical treatment
  • Norton Rose Fulbright Canada LLP
  • Canada
  • May 14 2015

Bayer Inc. (Bayer) distributes a combination oral contraceptive tablet under the brand name YAZ (drospirenone and ethinylestradiol


Pharma in brief Ontario Court of Appeal closes the door on generic manufacturer claim for unjust enrichment under section 8 of the PM(NOC) Regulations
  • Norton Rose Fulbright Canada LLP
  • Canada
  • May 11 2015

On May 5, 2015, the Court of Appeal for Ontario dismissed Apotex’s appeal from the Ontario Divisional Court, which struck out Apotex’s claim for